MARKET

NRIX

NRIX

Nurix Therapeutics, Inc.
NASDAQ
16.85
+0.90
+5.64%
After Hours: 16.85 0 0.00% 16:10 02/06 EST
OPEN
16.29
PREV CLOSE
15.95
HIGH
17.03
LOW
16.26
VOLUME
836.57K
TURNOVER
--
52 WEEK HIGH
22.50
52 WEEK LOW
8.18
MARKET CAP
1.73B
P/E (TTM)
-5.5221
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NRIX last week (0126-0130)?
Weekly Report · 6d ago
Analysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Nurix Therapeutics (NRIX)
TipRanks · 01/31 17:50
Nurix Therapeutics Exposed to Significant Foreign Exchange Risk Amid Unhedged Currency Exposure
TipRanks · 01/30 06:00
Nurix Therapeutics Is Maintained at Overweight by Piper Sandler
Dow Jones · 01/29 16:42
Nurix Therapeutics Price Target Raised to $35.00/Share From $32.00 by Piper Sandler
Dow Jones · 01/29 16:42
Piper Sandler Maintains Overweight on Nurix Therapeutics, Raises Price Target to $35
Benzinga · 01/29 16:31
Nurix Therapeutics Is Maintained at Outperform by RBC Capital
Dow Jones · 01/29 16:14
Nurix Therapeutics Price Target Raised to $30.00/Share From $28.00 by RBC Capital
Dow Jones · 01/29 16:14
More
About NRIX
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.

Webull offers Nurix Therapeutics Inc stock information, including NASDAQ: NRIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRIX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NRIX stock methods without spending real money on the virtual paper trading platform.